The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index; 25 of the 47 sources its claims cite were checked for support.
Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials
Open accessAbstract
Abstract Background Exploratory analysis to determine the effect of semaglutide versus comparators on high-sensitivity C-reactive protein (hsCRP) in subjects with type 2 diabetes. Methods Trials of once-weekly subcutaneous (SUSTAIN 3) and once-daily oral (PIONEER 1, 2, 5) semaglutide with hsCRP data were analyzed. Subjects with type 2 diabetes (N = 2482) received semaglutide (n = 1328) or comparators (placebo, n = 339; exenatide extended-release, n = 405; empagliflozin, n = 410). hsCRP ratio to baseline at end-of-treatment was analyzed overall, by clinical cutoff (< 1.0, ≥ 1.0 to ≤ 3.0, or > 3.0 mg/L), by tertile, and by estimated glomerular filtration rate in PIONEER 5 (a trial which was conducted in a population with type 2 diabetes and chronic kidney disease [CKD]). Mediation analyses assessed the effect of change in glycated hemoglobin (HbA 1c ) and/or change in body weight (BW) on hsCRP reductions. Results Geometric mean baseline hsCRP was similar across trials (range 2.7–3.0 mg/L). Semaglutide reduced hsCRP levels by clinical cutoffs and tertiles from baseline to end-of-treatment in all trials versus comparators (estimated treatment ratios [ETRs] versus comparators: 0.70–0.76; p < 0.01) except versus placebo in PIONEER 5 (ETR [95% CI]: 0.83 [0.67–1.03]; p > 0.05). The effect of semaglutide on hsCRP was partially mediated (20.6–61.8%) by change in HbA 1c and BW. Conclusions Semaglutide reduced hsCRP ratios-to-baseline versus comparators in subjects with type 2 diabetes (not significant with CKD). This effect was partially mediated via reductions in HbA 1c and BW and potentially by a direct effect of semaglutide. Semaglutide appears to have an anti-inflammatory effect, which is being further investigated in ongoing trials. Trial registrations: ClinicalTrials.gov identifiers: NCT01885208 (first registered June 2013), NCT02906930 (first registered September 2016), NCT02863328 (first registered August 2016), NCT02827708 (first registered July 2016).
Overview
CoChat Summary
TL;DR
In exploratory patient-level analyses of SUSTAIN 3 and PIONEER 1, 2, and 5, semaglutide reduced high-sensitivity C-reactive protein (hsCRP) ratios-to-baseline versus comparators in subjects with type 2 diabetes, except versus placebo in PIONEER 5 (CKD). The effect was partially mediated by reductions in HbA1c and body weight, with evidence suggesting a possible direct anti-inflammatory effect.
Key findings
- Semaglutide significantly reduced hsCRP versus comparators in SUSTAIN 3, PIONEER 1, and PIONEER 2: SUSTAIN 3 semaglutide 1.0 mg vs exenatide ER 2.0 mg reduced hsCRP by 25% (ETR 0.75 [95% CI 0.65–0.88]; p < 0.001); PIONEER 1 oral semaglutide 7 mg and 14 mg vs placebo reduced by 28% and 24% (ETR 0.72 [0.59–0.89]; p < 0.01 and 0.76 [0.62–0.93]; p < 0.01); PIONEER 2 semaglutide 14 mg vs empagliflozin 25 mg reduced by 30% (ETR 0.70 [0.61–0.80]; p < 0.0001).
- In PIONEER 5 (type 2 diabetes with CKD), oral semaglutide vs placebo showed a nonsignificant trend: ETR 0.83 [95% CI 0.67–1.03]; p = 0.08.
- Mediation analyses showed the effect of semaglutide on hsCRP was partially mediated by change in HbA1c (18.5–35.6%), change in body weight (5.7–57.0%), and combined HbA1c and body weight (20.6–61.8%).
- Geometric mean baseline hsCRP was similar across trials (range 2.7–3.0 mg/L).
Methods
- Exploratory patient-level analyses of phase 3 randomized trials with hsCRP data: SUSTAIN 3 and PIONEER 1, 2, and 5. Subjects with type 2 diabetes (N = 2482) received semaglutide (n = 1328) or comparators (placebo, n = 339; exenatide extended-release, n = 405; empagliflozin, n = 410); 2471 of 2482 randomized subjects (99.6%) had baseline hsCRP and were included. Treatment durations were 56 weeks (SUSTAIN 3), 52 weeks (PIONEER 2), and 26 weeks (PIONEER 1 and 5); PIONEER 5 enrolled subjects with CKD (eGFR 30–59 mL/min/1.73 m²).
- hsCRP ratios to baseline at end-of-treatment were analyzed using mixed models for repeated measurements (MMRM) with log-transformed hsCRP, treatment arm as fixed effect, baseline log hsCRP as covariate, nested within visit. Subgroup analyses included baseline hsCRP clinical cutoffs (< 1.0, ≥ 1.0 to ≤ 3.0, > 3.0 mg/L), hsCRP tertiles, sex, statin use, and eGFR.
- Mediation analyses assessed change in HbA1c and/or body weight as mediators of the semaglutide effect on hsCRP, separately and combined, for pooled semaglutide arms versus comparators.
Limitations
- The paper states the analysis was exploratory, lacked hard endpoints, had low hsCRP testing frequency, lacked data on other inflammation markers, and had relatively short follow-up (26–56 weeks). Data could not be pooled across trials due to differences in trial duration, except for baseline characteristics. hsCRP data are highly variable and outliers may dominate absolute change; ratios may be overly sensitive at low baseline hsCRP. Mediation analyses did not use all mediator values and trials were not powered for mediation analyses.
- The paper also notes no adjustment for multiplicity was performed, and some ETRs were not significant possibly due to lack of statistical power from small sample size.
- Evident from the text: the PIONEER 5 CKD population showed a nonsignificant hsCRP reduction versus placebo, and the analysis was limited to approved maintenance doses of semaglutide.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
21 Valid · 0 Not valid · 6 Not checked · 64 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“hsCRP data collected in SUSTAIN 2, 4, and 5 trials [22–24] were not used due to technical issues during sample collection — the hsCRP analysis assay was found to have a negative bias (an under-recovery of up to –25% at hsCRP concentrations below 5 mg/L), which affected a proportion of the samples.”
§ Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials > Methods > Trial designs and patient populations
What the sources say
- Not checked — no full text of the sourcecites [22] Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5:341–54. source
- Not checked — no full text of the sourcecites [23] Aroda VR, Bain SC, Cariou B, Piletic M, Rose L, Axelsen M, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5:355–66. source
- Partly supportedcites [24] Rodbard HW, Lingvay I, Reed J, de la Rosa R, Rose L, Sugimoto D, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103:2291–301. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“elevated hsCRP has been found to be predictive of major adverse CV events and death in individuals with or without type 2 diabetes and/or previous CV events [35].”
§ Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials > Discussion
What the sources say
- Partly supportedcites [35] Kengne AP, Batty GD, Hamer M, Stamatakis E, Czernichow S. Association of C-reactive protein with cardiovascular disease mortality according to diabetes status: pooled analyses of 25,979 participants from four UK prospective cohort studies. Diabetes Care. 2012;35:396–403. sourceExperimental — accuracy not yet measured
The Results section ('CRP and outcomes overall and by diabetes status'; page unavailable) reports that higher CRP was associated with cardiovascular and all-cause mortality in people with and without diabetes. The study assessed mortality, not the broader category of major adverse cardiovascular events, and the passages do not establish the claimed association separately for people with and without previous cardiovascular events. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Decreases in hsCRP have also been observed with other classes of antihyperglycemic drug (metformin, dipeptidyl peptidase-4 inhibitors, and SGLT-2 inhibitors), but with less consistency than with GLP-1RAs [27].”
§ Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials > Discussion
What the sources say
- Partly supportedcites [27] Katsiki N, Ferrannini E. Anti-inflammatory properties of antidiabetic drugs: a “promised land” in the COVID-19 era? J Diabetes Complications. 2020;34:107723. sourceExperimental — accuracy not yet measured
The Sitagliptin and SGLT2-inhibitor sections report both hsCRP decreases and studies with no decrease, consistent with mixed results. The Metformin section reports decreases in CRP, but its only explicit hsCRP finding is no effect; it therefore does not substantiate the claim that hsCRP decreases were observed with metformin. The GLP-1 RA section also reports mixed findings, so the broader comparison of consistency is not clearly established. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“the hsCRP reduction observed with the GLP-1RA semaglutide suggests that it might exert anti-inflammatory effects.”
§ Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials > Discussion
What the sources say
- Not checked — no full text of the sourcecites [1] Masters SL, Latz E, O’Neill LA. The inflammasome in atherosclerosis and type 2 diabetes. Sci Transl Med. 2011;3:81ps17. source
- Partly supportedcites [2] Tsalamandris S, Antonopoulos AS, Oikonomou E, Papamikroulis GA, Vogiatzi G, Papaioannou S, et al. The role of inflammation in diabetes: current concepts and future perspectives. Eur Cardiol. 2019;14:50–9. sourceExperimental — accuracy not yet measured
The “Drugs with Pleiotropic Effects” section says GLP-1 receptor agonists have anti-inflammatory properties, supporting the tentative inference about that drug class. It does not report an hsCRP reduction with semaglutide, so the drug-specific observation is not supported by this paper. (LLM, conf=0.86)
- Partly supportedcites [37] Rakipovski G, Rolin B, Nøhr J, Klewe I, Frederiksen KS, Augustin R, et al. The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE(-/-) and LDLr(-/-) mice by a mechanism that includes inflammatory pathways. JACC Basic Transl Sci. 2018;3:844–57. sourceExperimental — accuracy not yet measured
The Results section reports that semaglutide reduced inflammatory markers in mice, supporting the possibility of anti-inflammatory effects. But the paper attributes the reported hsCRP reduction to liraglutide in a clinical study, not to semaglutide; it therefore does not support the claim’s stated basis for that inference. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [38] Kaul S. Mitigating cardiovascular risk in type 2 diabetes with antidiabetes drugs: a review of principal cardiovascular outcome results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 trials. Diabetes Care. 2017;40:821–31. source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 2471 of 2482 randomized subjects (99.6%) had an hsCRP measurement at baseline and were included in the analyses.”
§ Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials > Results > Baseline characteristics
plainn = 2,482- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
27 more claims
Create a free account to see all 91 claims and every source verdict.
- Probably not a substantial claim. 37
- It may state two separate claims as one. 39
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Instead of reporting distinct RCT results, the only data available are exploratory post-hoc analyses of hs-CRP that pool individual-level data across trials [Mosenzon et al., 2022 (25); Verma et al., 2023 (26)].”
From Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis (2026) · cites this paper as Mosenzon et al., 2022 (25)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“The inflammatory biomarkers included in our eligibility criteria were not prospectively measured in the major semaglutide cardiovascular outcome trials (SUSTAIN-6, PIONEER-6, SELECT), and the information that is currently available comes solely from post-hoc pooled analyses (25, 26).”
From Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis (2026) · cites this paper as [25]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These animal data are in line with findings from human studies [57, 79–81].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1RAs have effects on systemic inflammation such as reduction in high-sensitivity C-reactive protein (hs-CRP) that are not mediated by weight loss or glycemic control [15, 27, 28].”
From evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease (2025) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the semaglutide SUSTAIN and PIONEER trials, reductions in glucose and weight explained only 20%–60% of the observed CRP reductions (17).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [17]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials > Discussion
“This exploratory analysis suggests that s.c. and oral semaglutide significantly reduced hsCRP levels versus comparators in subjects with type 2 diabetes. The comparators were placebo in PIONEER 1 and PIONEER 5, and active comparators in SUSTAIN 3 (exenatide ER) and PIONEER 2 (empagliflozin).”
§ Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials > Results > Estimated treatment ratios and ratio-to-baseline at end-of-treatment by trial
“In PIONEER 5, there was a nonsignificant trend of reduction, as the ETR at week 26 for oral semaglutide versus placebo was 0.83 [95% CI, 0.67–1.03]; p = 0.08; Fig. 1.”
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“semaglutide and CV non-inferiority with oral semaglutide vs placebo, respectively [14, 15].”
Self-citationRosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401 · cited 1×
“According to the Centers for Disease Control and Prevention/American Heart Association guidelines, hsCRP < 1 mg/L indicates low CV risk, hsCRP of 1–3 mg/L indicates intermediate CV risk, and hsCRP > 3 mg/L indicates high CV risk [7].”
MethodOnce-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationOral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Self-citationDavies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citationThe Role of Inflammation in Diabetes: Current Concepts and Future Perspectives
Tsalamandris, S., Antonopoulos, A. S., Oikonomou, E., Papamikroulis, G.-A., Vogiatzi, G., Papaioannou, S., Deftereos, S., & Tousoulis, D. (2019) · European Cardiology Review · doi:10.15420/ecr.2018.33.1 · Cited by 1,381
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Mediation analysis with multiple mediators
VanderWeele, T., & Vansteelandt, S. (2014) · Epidemiologic Methods · doi:10.1515/em-2012-0010 · Cited by 858
Genetically elevated C-reactive protein and ischemic vascular disease
Zacho, J., Tybjærg-Hansen, A., Jensen, J. S., Grande, P., Sillesen, H., & Nordestgaard, B. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707402 · Cited by 839
Cited by
Bonaca, M. P., Catarig, A.-M., Houlind, K., Ludvik, B., Nordanstig, J., Ramesh, C. K., Rasouli, N., Sourij, H., Videmark, A., & Verma, S. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00509-4 · Cited by 176
Cummings, J. L., Atri, A., Feldman, H. H., Hansson, O., Sano, M., Knop, F. K., Johannsen, P., León, T., & Scheltens, P. (2025) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01666-7 · Cited by 168
Low-Grade Chronic Inflammation: a Shared Mechanism for Chronic Diseases
Cifuentes, M., Verdejo, H., Castro, P., Corvalán, A. H., Ferreccio, C., Quest, A. F. G., Kogan, M. J., & Lavandero, S. (2024) · Physiology · doi:10.1152/physiol.00021.2024 · Cited by 198
Amezcua-Castillo, E., González‐Pacheco, H., Martín, A. S.-S., Méndez-Ocampo, P., Gutiérrez-Moctezuma, I., Massó, F., Sierra‐Lara, D., Springall, R., Rodríguez, E., Arias‐Mendoza, A., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11092444 · Cited by 163
Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits
Wong, C. K., & Drucker, D. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194751 · Cited by 112
“Multiple GLP-1 medicines, including exenatide (15), liraglutide (16), semaglutide (17, 18), and tirzepatide (19), reduce plasma CRP levels in people living with T2D and/or obesity.”
Metadata
- Authors
- Mosenzon, O., Capehorn, M. S., De Remigis, A., Rasmussen, S., Weimers, P., & Rosenstock, J.
- Affiliations
- Hebrew University of Jerusalem (IL)
- The Rotherham NHS Foundation Trust (GB)
- Novo Nordisk (Denmark) (DK)
- Velocity Clinical Research (United States) (US)
- Corresponding author
- Mosenzon, Ofri
- Venue
- Cardiovascular Diabetology
- Published
- 2022-09-02
- Volume
- 21
- Issue
- 1
- Pages
- 172-172
- ISSN
- 1475-2840 (ISSN-L)
- PMC
- PMC9440529
- OpenAlex
- W4294542663
- Cited by
- 91
- References
- 47
- Citations by year
- 2026: 35 · 2025: 28 · 2024: 15 · 2023: 12 · 2022: 1
- FWCI
- 10.37
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cardiovascular Diabetology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- semaglutide, high-sensitivity C-reactive protein, type 2 diabetes, anti-inflammatory activity, HbA1c, body weight, mediation analysis, chronic kidney disease, exenatide extended-release, empagliflozin, SUSTAIN trials, PIONEER trial, GLP-1 receptor agonists, estimated glomerular filtration rate
- MeSH terms
- Semaglutide, Body Weight, C-Reactive Protein, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Glycated Hemoglobin, Humans, Randomized Controlled Trials as Topic, Treatment Outcome, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials. https://app.cochat.ai/papers/10.1186/s12933-022-01585-7
- The paper
- Mosenzon, O., Capehorn, M. S., De Remigis, A., Rasmussen, S., Weimers, P., & Rosenstock, J. (2022). Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-022-01585-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.